Use of high doses of deferoxamine (Desferal) in an adult patient with acute iron overdosage.
Deferoxamine, a specific chelator of ferric iron, has recognized efficacy in the treatment of acute iron overdosage. Toxicological references, however, vary in the preferred route of administration and recommended maximum dosage. A 19-year-old female patient ingested an estimated 50-60 ferrous sulfate tablets, representing approximately 9.8-11.7 g of elemental iron. At the time of admission, she had a serum iron level of 915 micrograms/dL and a total iron binding capacity of 515 micrograms/dL. She was treated with intravenous deferoxamine at 15 mg/kg/h via continuous infusion for a total dose of 37.1 g over a 52-h period until her urine exhibited no evidence of deferoxamine-iron chelation products for 24 consecutive hours. This paper supports the safety and efficacy of a slow IV infusion of deferoxamine in an adult patient, using a regimen recommended for pediatric patients.
D000328:Adult; D002648:Child; D003676:Deferoxamine / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D005296:Ferrous Compounds / Q000506:poisoning*; D005751:Gastric Lavage; D006801:Humans; D007263:Infusions, Parenteral; D007501:Iron / Q000097:blood / Q000506:poisoning*
D005296:Ferrous Compounds; C020748:ferrous sulfate; D007501:Iron; D003676:Deferoxamine